BeOne Medicines (ONC) Q1 2025 earnings summary

Executive summary

• Achieved GAAP profitability in Q1 2025, with net income of $1.3 million and $11 million operating income, reversing a $251 million loss year-over-year, driven by 49% revenue growth to $1.12 billion and strong BRUKINSA performance.

• BRUKINSA became the U.S. and global market leader in BTK inhibitors by revenue, with global sales up 62% to $792 million and U.S. sales up 60% to $563 million.

• Advanced late-stage hematology and solid tumor pipelines, with multiple pivotal and proof-of-concept trials initiated or completed enrollment and several readouts expected in 2025.

• Shareholders approved redomiciling to Switzerland and a company name change to BeOne Medicines Ltd., reflecting global ambitions.

• Expanded global commercial footprint, treating over 1.7 million cancer patients and launching in more than 80 markets.

Financial highlights

• Q1 2025 revenue reached $1.12 billion, up 49% year-over-year from $752 million in Q1 2024.

• BRUKINSA sales were $792 million, up 62% year-over-year; TEVIMBRA sales were $171 million, up 18%.

• GAAP operating income was $11 million, compared to a $261 million loss in Q1 2024; adjusted income from operations was $139 million.

• Gross margin improved to 85.1% (GAAP) and 85.5% (adjusted), up from 83% in Q1 2024.

• Operating cash flow improved by $353 million year-over-year to $44 million.

Outlook and guidance

• Full-year 2025 revenue guidance affirmed at $4.9–$5.3 billion, with strong growth expected from BRUKINSA's global expansion.

• GAAP gross margin expected in the mid-80% range; operating expenses projected at $4.1–$4.4 billion.

• Committed to achieving full-year GAAP operating income break-even and positive operating cash flow.

• Guidance incorporates estimated impacts of tariffs, with mitigated exposure due to global manufacturing investments.